Premium
Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate
Author(s) -
TomasiakLozowska M. M.,
Misztal T.,
Rusak T.,
BranskaJanuszewska J.,
BodzentaLukaszyk A.,
Tomasiak M.
Publication year - 2017
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13054
Subject(s) - asthma , fibrinolysis , medicine , hemostasis , plasminogen activator inhibitor 1 , spirometry , plasminogen activator , fibrinogen , eosinophil , tissue plasminogen activator , immunology , gastroenterology
The aim of this study was to assess whether steroid‐naïve asthma modulates hemostasis. We evaluated the clot retraction rate ( CRR ), fibrinolysis rate ( FR ), clot density ( CD ) (by confocal microscopy), plasma levels of plasminogen activator inhibitor ( PAI ‐1), and factor XIII ( FXIII ), NO in exhaled breath (FE NO ), spirometry ( FEV 1 ) and eosinophil count ( EOS ) in 36 patients with allergic, steroid‐naïve asthma and in 34 healthy controls. We observed significantly ( P < 0.001) reduced CRR , FR , and FEV 1 and increased FE NO , EOS , PAI ‐1, FXIII , and CD in patients with asthma compared with controls. In patients with asthma, FR negatively correlated with CD , FXIII , PAI ‐1, FE NO , and EOS and positively with FEV 1 . FXIII positively correlated with CD . Clot retraction rate negatively correlated with FE NO and positively with FEV 1 (all P < 0.001). These novel findings suggest that asthma itself is associated with decreased CRR and reduced fibrinolytic potential resulting from alterations in clot architecture and elevated levels of plasma FXIII and PAI ‐1.